What Happened? A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2026 earnings conference call at 4:30 pm ET on Wednesday, November 4 ...

If you had looked at Myriad Genetics in October 2025, seen bullish talk about genomics, AI and precision medicine, then ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 5% in the afternoon session after Craig-Hallum analyst ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) today announce a collaboration to advance new prostate ...

Myriad Genetics partners with AWS to enhance Image Genius, speeding up document processing, and improving insurance workflows for diagnostics.

Myriad Genetics, Inc. has launched a new educational website called "Know More Sooner," aimed at providing detailed information about reproductive and prenatal genetic testing. The site seeks to ...

TD Cowen raised its Myriad Genetics target from USD 4.00 to USD 4.50 on October 13, 2026, while maintaining a Hold rating, ...

Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.

SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) ...

Myriad Genetics, Inc. and SOPHiA GENETICS announced a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with ...